Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 4/20 | 0.53 |
| ▸ | CHUK | O15111 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 14/20 | 0.43 |
| ▸ | CASP3 | P42574 | 10/20 | 0.43 |
| ▸ | CASP7 | P55210 | 10/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | CDK7 | P50613 | 3/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990774 | 1.00 | MAP3K5 (0.53) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2988005 | 0.90 | IKBKB (0.53) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2992991 | 0.87 | IKBKB (0.68) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2991038 | 0.85 | MAP3K5 (0.71) | MAP3K5IKBKBCHUKCIT | |
| SCHEMBL2977496 | 0.85 | MAP3K5 (0.71) | MAP3K5IKBKBCHUKCIT | |
| SCHEMBL2982135 | 0.85 | IKBKB (0.70) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2990237 | 0.85 | IKBKB (0.69) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2991897 | 0.85 | IKBKB (0.70) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2985661 | 0.84 | MAP3K5 (0.72) | MAP3K5IKBKBCHUKCYP2C9CIT | |
| SCHEMBL2993164 | 0.82 | MAP3K5 (0.54) | MAP3K5IKBKBCHUKCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | claimed |
| EP-2162455-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | Glaxo Group Limited (GB) | 2010-03-17 | — | — | EP | claimed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | claimed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| EP-2162455-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | Glaxo Group Limited (GB) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | MAP3K5 7/4885IKBKB 11/4885CHUK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.